Sort
4,870 grants matching “glp 1”
Therapeutic Antibody for CMV
$997,600Lawrence Michael Kauvar · Trellis Bioscience, Inc. · SB1 · FY2018 · AI
ErythroMer: Nanoscale BioSynthetic Red Cell Substitute
$997,590Esma Alp · Kalocyte, Inc. · R44 · FY2024 · HL
Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer
$997,515Valerie Humblet · Collagen Medical, Llc · R44 · FY2016 · CA
Development of a nitric oxide-releasing antiviral gel for the treatment of cervical HPV infections and prevention of downstream malignancies in women
$997,413Carri Geer · Novan, Inc. · R44 · FY2020 · AI
Therapeutic factor XI blockade for sepsis
$997,083Erik Ian Tucker · Aronora, Inc. · R44 · FY2016 · HL
Targeting superbugs: discovery and development of new broad-spectrum lipopeptides
$996,973Jian Li · Monash University · R01 · FY2016 · AI
Preclinical development of teixobactin, a new antibiotic
$996,881Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R44 · FY2019 · AI
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
$996,814Jeff T Hutchins · Inhalon Biopharma, Inc. · SB1 · FY2024 · AI
The Next-Generation Developmental and Reproductive Toxicology (DART) Assay using High-Content Analysis of Genetically Diverse C. elegans Populations
$996,687Evan Hegarty · Vivoverse, Llc · R44 · FY2023 · ES
Host Directed Orynotide for MDR Gram Negative Bacterial Infections
$996,458Justin Blaine Schaal · University Of Southern California · R01 · FY2024 · AI
Teixobactin Development for Anthrax
$996,402Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R44 · FY2021 · AI
Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management
$996,212Bozena Korczak · Vascular Vision Pharmaceuticals Company · R44 · FY2022 · HL
Targeting leukocyte metabolism to treat human autoimmune disease
$996,128Jay L Rothstein · Immunext, Inc. · R44 · FY2019 · AI
A NOVEL PRECISION MEDICINE APPROACH FOR OBESITY: A RANDOMIZED, MULTI-CENTER TRIAL
$996,003Mark Bagnall · Phenomix Sciences, Llc · R44 · FY2024 · DK
A NOVEL PRECISION MEDICINE APPROACH FOR OBESITY: A RANDOMIZED, MULTI-CENTER TRIAL
$995,866Mark Bagnall · Phenomix Sciences, Llc · R44 · FY2025 · DK
Targeting leukocyte metabolism to treat human autoimmune disease
$995,802Jay L Rothstein · Immunext, Inc. · R44 · FY2018 · AI
Targeting leukocyte metabolism to treat human autoimmune disease
$995,802Jay L Rothstein · Immunext, Inc. · R44 · FY2020 · AI
In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV
$995,652Richard A Cone · Mucommune, Llc · R44 · FY2021 · AI
Naloxone Nasal Spray Development
$995,554Daniel Paul Wermeling · Antiop, Inc. · R42 · FY2014 · DA
Spectroscopic Localization of Breast Cancer
$995,474David A. Benaron · Spectros Corporation · R44 · FY2007 · CA
ErythroMer: Nanoscale BioSynthetic Red Cell Substitute
$995,470Esma Alp · Kalocyte, Inc. · R44 · FY2025 · HL
A Vaccine for Lymphatic Filariasis, LFGuardâ¢
$995,460Darrick Albert Carter · Pai Life Sciences, Inc. · R44 · FY2024 · AI
Aerosolized Vitamin A: Developing a Prevention for Hyperoxic Lung Injury and Bronchopulmonary Dysplasia, with Focus on Neonatal Lung Maturation
$995,121Craig Gelfand · Advent Therapeutics, Inc. · R44 · FY2023 · HL
Advancing a novel potent double anti-HCV nucleoside analog combination treatment for the OUD population to the clinic
$995,102Klaus Klumpp · Riboscience, Llc · R44 · FY2020 · DA
Advancing a novel potent double anti-HCV nucleoside analog combination treatment for the OUD population to the clinic
$995,102Klaus Klumpp · Riboscience, Llc · R44 · FY2021 · DA